Undisclosed dilEVry based siRNA cancer therapeutic / VesiCURE Therap - LARVOL DELTA

Exosomes functionally deliver siRNAs in vivo to repress tumor growth (PRNewswire) - "VesiCURE Therapeutics Co. Ltd...recently released a preprint on BioRxiv...In this study, the VesiCURE team utilized their 'dilEVry' platform to load exosomes with tumor-inhibiting siRNAs. When administered intratumorally in a CDX tumor model, this approach resulted in progressive inhibition of tumor growth overtime. Furthermore, a biodistribution study exhibited a notable accumulation of dye-labeled exosomes within the tumors, strongly indicating the potential of exosomes for delivering siRNAs into tumors through intravenous infusion, a development currently underway in-house."

Preclinical • Oncology • Solid Tumor